Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
On Tuesday, JMP Securities reaffirmed their Market Outperform rating on Pharvaris B.V. (NASDAQ: PHVS) with a steady price target of $55.00, representing significant upside from the current price of $17.27. With a market capitalization of $937 million and an overall Financial Health score of "FAIR" according to InvestingPro, the company shows promise despite current losses. The firm's analyst, Jonathan Wolleben, highlighted the company's progress in its clinical trials, particularly its Phase 3 study of the extended-release version of deucrictibant for prophylactic treatment of Hereditary Angioedema (HAE).Want deeper insights? InvestingPro subscribers have access to over 20 additional premium metrics and exclusive analysis tools. This trial is anticipated to yield results in the second half of 2026.
Pharvaris is also set to present data from the RAPIDe-2 trial, an open-label extension (OLE) of the Phase 2 RAPIDe-1 study. The company maintains a strong financial position with a current ratio of 19.08 and minimal debt, providing adequate runway for its clinical development programs. The RAPIDe-1 trial demonstrated promising outcomes, with deucrictibant showing a rapid median onset of symptom relief in 1.1 hours and complete resolution of attacks in a median time of 11.5 hours for HAE patients.
The company remains active in patient enrollment for its ongoing Phase 3 RAPIDe-3 trial, which is evaluating deucrictibant as a treatment for HAE attacks. Top-line data from this trial are expected to be released in the first quarter of 2026. The stock currently trades below its InvestingPro Fair Value, with analysts maintaining a strong buy consensus rating of 1.71 (where 1 is Strong Buy and 5 is Strong Sell).
Hereditary Angioedema is a rare genetic condition characterized by recurrent episodes of severe swelling, which can be life-threatening. Pharvaris's work in developing deucrictibant aims to address the needs of patients suffering from this condition by providing a potentially more effective and faster-acting treatment option.
The reaffirmation of the Market Outperform rating and the $55.00 price target by JMP Securities reflects confidence in Pharvaris's clinical development strategy and the potential market impact of its product candidate, deucrictibant, upon successful trial outcomes and eventual market entry.
In other recent news, Pharvaris B.V. has seen a significant adjustment in its stock target, as JMP Securities analyst Jonathan Wolleben raised it to $55.00 from the previous $46.00. The analyst maintained a Market Perform rating on the stock, citing Pharvaris's unique standing as the only company with an oral candidate for both prophylaxis and on-demand treatment of Hereditary Angioedema (HAE). Wolleben underscored the potential of Pharvaris's deucrictibant to capture a substantial portion of the prophylactic market, based on promising data from Phase 2 trials and expectations for Phase 3 results.
The analyst also noted that Pharvaris's deucrictibant shares the same mechanism of action as icatibant, a commonly used drug for HAE treatment. He suggested that patients may prefer deucrictibant over KalVista Pharmaceuticals (NASDAQ:KALV), Inc.'s sebetralstat, should both drugs receive approval. The updated price target reflects a revised revenue forecast for Pharvaris's prophylactic treatment, aligning with market models for comparable companies such as Attune Pharmaceuticals, Inc. and BioCryst Pharmaceuticals (NASDAQ:BCRX), Inc. Other factors contributing to the new $55 risk-adjusted, Discounted Cash Flow (DCF)-derived price target include a larger addressable patient population.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.